Solutions for Nephrology - Medical / Health Care
When Otsuka saw a need for clinical expertise and research in the nephrology space, we decided to lead the way. For more than 20 years, we have been bringing our research and expertise to this therapeutic area. We have focused on developing novel drugs in areas of unmet need, such as autosomal dominant polycystic kidney disease and hyponatremia, that have changed the treatment landscape. Our long-term perseverance has led to major breakthroughs, giving patients renewed hope and clinicians more options than ever before.
Details
Otsuka’s perseverance in developing treatments for people living with kidney disease has led to breakthroughs that have helped change the landscape of treatment options and set the stage for other new developments in nephrology. The approval of a treatment for autosomal dominant polycystic kidney disease (ADPKD) was the result of decades of research and commitment, and provided a first-in-class treatment option for ADPKD.
We are continuing to build upon our legacy with an ongoing investment in nephrology. With changes in the measurement of outcomes that may impact disease progression, medical breakthroughs are on the horizon. We are working both internally and in collaboration with other companies that share
our values and dedication to bring forth more options in nephrology care. In 2018, Visterra joined the Otsuka corporate family to further our commitment to establish our leadership in nephrology.
Our dedication goes beyond clinical advancements. In addition to drug development, we have spent years advocating on behalf of patients through programs and institutions focused on kidney disease. This continued commitment to patients, researchers, and healthcare professionals has helped us develop a proven expertise in nephrology. We will continue to serve our patients and clinicians each and every day, so they can achieve more than they thought was possible.
